Company Description

PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of cutting-edge aesthetic medicines and therapeutic products.

The company’s lead product includes EL-22, a first-in-class engineered probiotic approach to address obesity’s pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists.

It is also involved in the medical scientific research and development activities, as well as operates investment firms.

The company was formerly known as Elevai Labs, Inc. and changed its name to PMGC Holdings Inc. in December 2024.

PMGC Holdings Inc. was incorporated in 2020 and is based in Newport Beach, California.

PMGC Holdings Inc.

Country	United States
Founded	2020
IPO Date	Nov 21, 2023
Industry	Biotechnology
Sector	Healthcare
Employees	3
CEO	Graydon Bensler

Contact Details

Address: 120 Newport Center Drive, Suite 249 Newport Beach, California 92660 United States
Phone	866-445-4886
Website	pmgcholdings.com

Stock Details

Ticker Symbol	ELAB
Exchange	NASDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
IPO Price	$4.00
CIK Code	0001840563
ISIN Number	US73017P2011
Employer ID	85-1399981
SIC Code	2834

Key Executives

Name	Position
Graydon Bensler C.F.A.	Chief Executive Officer, Chief Financial Officer, Secretary and Director
Braeden William Lichti	Executive Chairman of the Board

Latest SEC Filings

Date	Type	Title
Aug 14, 2025	PRE 14C	Filing
Aug 13, 2025	10-Q	Quarterly Report
Jul 31, 2025	8-K	Current Report
Jul 22, 2025	8-K	Current Report
Jul 11, 2025	8-K	Current Report
Jun 24, 2025	8-K	Current Report
Jun 18, 2025	8-K	Current Report
Jun 9, 2025	8-K	Current Report
May 16, 2025	8-K	Current Report
May 15, 2025	SCHEDULE 13G/A	Filing

View All SEC Filings